A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Apolipoprotein C-III (apoC-III) inhibits triglyceride hydrolysis and has been implicated in coronary artery disease. Through a genome-wide association study, we have found that about 5% of the Lancaster Amish are heterozygous carriers of a null mutation (R19X) in the gene encoding apoC-III ( APOC3 ) and, as a result, express half the amount of apoC-III present in noncarriers. Mutation carriers compared with noncarriers had lower fasting and postprandial serum triglycerides, higher levels of HDL-cholesterol and lower levels of LDL-cholesterol. Subclinical atherosclerosis, as measured by coronary artery calcification, was less common in carriers than noncarriers, which suggests that lifelong deficiency of apoC-III has a cardioprotective effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function variants of APOC3 that result in reduced synthesis of the protein are associated with absent or low circulating apoCIII levels, increased efficiency of TG removal from TRL, and lower plasma TG levels,59,60”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, rare heterozygous LOF variants in APOC3 encoding apo C-III are associated with ∼50% reduced TG levels and significantly increased clearance of very-low-density lipoprotein (VLDL).8,9”
From Clinical review on triglycerides (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and is a genetically validated target to reduce ASCVD risk.8–10,64–66”
From Clinical review on triglycerides (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Founder populations (such as those from Finland and Iceland) have provided multiple examples of otherwise rare risk alleles driven to higher frequency locally through drift and/or selection49–52.”
From A brief history of human disease genetics (2020) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apolipoprotein C-III is a central regulator of triglyceride metabolism that limits the clearance of triglyceride-rich lipoproteins through inhibition of lipoprotein lipase and hepatic uptake of triglyceride-rich lipoprotein remnants. 6-8”
From Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (2025) · cites this paper as [7]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups
Detrano, R., Guerci, A. D., Carr, J. J., Bild, D. E., Burke, G., Folsom, A. R., Liu, K., Shea, S., Szklo, M., Bluemke, D. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa072100 · Cited by 2,989
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Goldstein, J. L., Schrott, H. G., Hazzard, W. R., Bierman, E. L., & Motulsky, A. G. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107332 · Cited by 1,443
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Cited by
Items 401–500 of 682
Colombo, M., Looker, H. C., Farran, B., Agakov, F. V., Brosnan, M. J., Welsh, P. I., Sattar, N. A., Livingstone, S. J., Durrington, P. N., Betteridge, D. J., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.05.014 · Cited by 17
Apo CIII Proteoforms, Plasma Lipids, and Cardiovascular Risk in MESA
Sinari, S. A., Koška, J., Hu, Y., Furtado, J. D., Jensen, M. K., Budoff, M. J., Nedelkov, D., McClelland, R. L., Billheimer, D. D., & Reaven, P. D. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319035 · Cited by 18
Yu, J., Huang, J., Liang, Y., Qin, B., He, S., Xiao, J., Wang, H., & Zhong, R. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-200 · Cited by 17
Key differences between apoC-III regulation and expression in intestine and liver
West, G., Rodia, C. N., Li, D., Johnson, Z. K., Dong, H., & Kohan, A. B. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.07.116 · Cited by 19
Shetty, S. K., Walzem, R. L., & Davies, B. S. J. (2020) · Journal of Lipid Research · doi:10.1194/jlr.d119000388 · Cited by 19
Silbernagel, G., Scharnagl, H., Kleber, M. E., Hoffmann, M. M., Delgado, G., Stojaković, T., Gary, T., Zeng, L., Ritsch, A., Zewinger, S., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.08.017 · Cited by 17
Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle
Valladolid‐Acebes, I., Berggren, P., & Juntti‐Berggren, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020932 · Cited by 18
Alantolactone suppresses APOC3 expression and alters lipid homeostasis in L02 liver cells
Yang, M., Zhao, H., Ai, H., Zhu, H., Wang, S., Bao, Y., & Li, Y. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.021 · Cited by 16
“TG is also a hallmark of lipid metabolism diseases and APOC3 can inhibit TG hydrolysis (Pollin et al., 2008).”
Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia
Hooper, A. J., Bell, D. A., & Burnett, J. R. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2408369 · Cited by 17
Bergmark, B. A., Marston, N., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Kang, Y. M., Murphy, S. A., Zhang, S. M., Lu, M. T., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.02.022 · Cited by 17
Shaik, A., & Rosenson, R. S. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07168-0 · Cited by 16
Kassai, A., Muniyappa, R., Levenson, A. E., Walter, M. F., Abel, B. S., Ring, M., Taylor, S. I., Biddinger, S. B., Skarulis, M. C., Görden, P., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3891 · Cited by 15
Morita, S., Sakurai, A., Nakano, M., Kitagawa, S., & Handa, T. (2010) · Lipids · doi:10.1007/s11745-010-3498-9 · Cited by 19
“able lipid profile and reduced subclinical coronary artery atherosclerosis [8].”
BackgroundMarston, N., Bergmark, B. A., Prohaska, T. A., Moura, F. A., Zimerman, A., Alexander, V. J., Kang, Y. M., Weinland, J., Ran, X., Murphy, S. A., et al. (2026) · Circulation · doi:10.1161/circulationaha.126.080012 · Cited by 22
Luk, A. O. Y., Fan, Y., Fan, B., Chow, E. W. K., & Tony, C. K. O. (2025) · Diabetologia · doi:10.1007/s00125-025-06482-8 · Cited by 19
Human Genetics of Atherothrombotic Disease and its Risk Factors
Rader, D. J. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305492 · Cited by 16
Glicksberg, B. S., Amadori, L., Akers, N. K., Sukhavasi, K., Franzén, O., Li, L., Belbin, G. M., Akers, K. L., Shameer, K., Badgeley, M. A., et al. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0542-3 · Cited by 16
Large-Scale Analysis of Apolipoprotein CIII Glycosylation by Ultrahigh Resolution Mass Spectrometry
Demus, D., Naber, A., Dotz, V., Jansen, B. C., Bladergroen, M. R., Nouta, J., Sijbrands, E. J. G., van Hoek, M., Nicolardi, S., & Wuhrer, M. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.678883 · Cited by 14
“Recently, the clinical interest for this protein has increased due to the promising results obtained from antisense oligonucleotide-based therapies for the reduction of apo-CIII and triglyceride levels (Pollin et al., 2008; Rocha et al., 2017; Reyes-Soffer et al., 2019; Taskinen et al., 2019).”
BackgroundInhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia
Larouche, M., Khoury, É., Brisson, D., & Gaudet, D. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01179-y · Cited by 15
Adaptive genetic variation and heart disease risk
Parnell, L. D., Lee, Y., & Lai, C. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283378e42 · Cited by 15
Brautbar, A., Virani, S. S., Belmont, J. W., Nambi, V., Jones, P. H., & Ballantyne, C. M. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m020404 · Cited by 14
Effect of Hypertriglyceridemia on Beta Cell Mass and Function in ApoC3 Transgenic Mice
Liu, Y., Cheng, X., Zhang, T., Lee, S., Yamauchi, J., Xiao, X., Gittes, G. K., Qu, S., Jiang, C., & Dong, H. H. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.707885 · Cited by 16
Lee, S. J., Mahankali, M., Bitar, A., Zou, H., Chao, E., Nguyen, H., González, J., Caballero, D., Hull, M. V., Wang, D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05163-w · Cited by 15
Sun, M., Chen, L., Liu, H., Ma, L., Wang, T., & Liu, Y. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0614-3 · Cited by 14
“In contrast, a recent study showed that non-mutated apoC3 gene carriers exhibited a favorable lipid profile, and revealed strong genetic evidence implicating the S2 allele in the development of atherosclerosis [18, 19].”
Discovering Biological Mechanisms of Exceptional Human Health Span and Life SpanPreprint
Milman, S., & Barzilai, N. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041204 · Cited by 14
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
“This approach has identified (and validated) an expanding number of new targets for pharmacological intervention across various indications, notably cardiovascular disease 310–312 .”
Bagdade, J. D., Barter, P. J., Quiroga, C., & Alaupovic, P. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.02.049 · Cited by 13
Obirikorang, C., Acheampong, E., Quaye, L., Yorke, J., Amos-Abanyie, E. K., Akyaw, P. A., Anto, E. O., Bani, S. B., Adu, E. A., & Batu, E. N. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227779 · Cited by 13
Liu, C., Lai, P., Guo, J., Wang, Y., & Xian, X. (2021) · Medical Review · doi:10.1515/mr-2021-0004 · Cited by 16
Guo, J., Wu, J., Wei, D., Wang, T., Hu, Y., Lin, Y., Chen, M., Yang, L., Wen, Y., Cai, Y., et al. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.113199 · Cited by 13
Radoviča-Spalviņa, I., Frīdmanis, D., Silamiķelis, I., Ņikitina-Zaķe, L., & Kloviņš, J. (2014) · Meta Gene · doi:10.1016/j.mgene.2014.07.006 · Cited by 14
Elosúa, R., Lluís-Ganella, C., & Lucas, G. (2009) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(09)71502-x · Cited by 16
Huang, H., Zeng, Z., Zhang, L., Liu, R. R., Li, X., Qiang, O., & Chen, Y. (2011) · Molecular Biology Reports · doi:10.1007/s11033-011-0914-z · Cited by 13
“[26] had ever found that Table 3 Genotypes and allele distributions of SNPs between obesity and non-obesity groups in CAD patients”
BackgroundTriglycerides Revisited to the Serial
Viecili, P. R. N., da Silva, B., Hirsch, G. E., Porto, F. G., Parisi, M. M., Castanho, A. R., Wender, M., & Klafke, J. Z. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.11.001 · Cited by 21
Treating Dyslipidemia in Type 2 Diabetes
Nelson, A. J., & Nicholls, S. J. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.005 · Cited by 14
An APOO Pseudogene on Chromosome 5q Is Associated With Low-Density Lipoprotein Cholesterol Levels
Montasser, M. E., O’Hare, E. A., Wang, X., Howard, A. D., McFarland, R. J., Perry, J. A., Ryan, K. A., Rice, K. M., Jaquish, C. E., Shuldiner, A. R., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034016 · Cited by 14
Self-citationGenetic variation in insulin‐induced kinase signaling
Wang, I. X., Ramrattan, G., & Cheung, V. G. (2015) · Molecular Systems Biology · doi:10.15252/msb.20156250 · Cited by 15
“For instance, it was previously reported that abnormal level of APOC3 led to hypertriglyceridemia in transgenic mice and humans (Carlson & Ballantyne, 1976; Ginsberg et al , 1986; Ito et al , 1990; Aalto-Seta¨la¨ et al , 1992; Pollin et al , 2008).”
Sequence-Based Analysis of Lipid-Related Metabolites in a Multiethnic Study
Feofanova, E. V., Yu, B., Metcalf, G., Liu, X., Muzny, D. M., Below, J. E., Wagenknecht, L. E., Gibbs, R. A., Morrison, A. C., & Boerwinkle, E. (2018) · Genetics · doi:10.1534/genetics.118.300751 · Cited by 14
Wang, Y., Selvaraj, M. S., Li, X., Li, Z., Holdcraft, J. A., Arnett, D. K., Bis, J. C., Blangero, J., Boerwinkle, E., Bowden, D. W., et al. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.09.003 · Cited by 15
Self-citationNaber, A., Demus, D., Slieker, R. C., Nicolardi, S., Beulens, J. W. J., Elders, P. J. M., Lieverse, A. G., Sijbrands, E. J. G., Hart, L. M. ‘., Wuhrer, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105365 · Cited by 12
“Consequently, it has been suggested that apo-CIII levels could be reduced by anti-apo-CIII antibody, antisense RNA, and silencing RNA therapies to reduce vascular disease risk [19–22].”
BackgroundUsing human genetics to predict the effects and side-effects of drugs
Stender, S., & Tybjærg‐Hansen, A. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000280 · Cited by 13
Xu, K., Guo, S., Zhao, T., Zhu, H., Jiao, H., Shi, Q., Pang, F., Li, Y., Li, G., Peng, D., et al. (2016) · BioMed Research International · doi:10.1155/2016/1648030 · Cited by 13
“triglyceride-rich lipoproteins and may contribute to the development of hyperlipidemia and other lipoprotein abnormalities in humans [17–19].”
BackgroundGenetic determinants of myocardial dysfunction
Li, X., & Zhang, P. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-104308 · Cited by 15
Maidman, S. D., Hegele, R. A., & Rosenson, R. S. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01258-8 · Cited by 14
Zhu, W., & Zhang, H. (2012) · Frontiers of Mathematics · doi:10.1007/s11464-012-0256-8 · Cited by 12
Therapeutic potential of antisense oligonucleotides for the management of dyslipidemia
Crooke, R. M., & Graham, M. J. (2011) · Clinical Lipidology · doi:10.2217/clp.11.59 · Cited by 11
Atherosclerotic cardiovascular disease in hyperalphalipoproteinemia due to LIPG variants
Cole, J., Blackhurst, D. M., Solomon, G. A. E., Ratanjee, B. D., Benjamin, R. L., & Marais, A. D. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.12.007 · Cited by 12
Pooja, P., Sharma, V., Meena, R. N., Ray, K., Panjwani, U., Varshney, R. K., & Sethy, N. K. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.730601 · Cited by 11
“ApoCIII gain of function mutations are associated with atherosclerosis and coronary heart disease (CHD) and contribute to the development of hypertriglyceridemia, whereas loss of function mutations are associated with lower levels of plasma triglycerides and attenuation of vascular inflammatory processes (Pollin et al…”
BackgroundHermel, M., Lieberman, M., Slipczuk, L. N., Rana, J. S., & Virani, S. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020459 · Cited by 12
“In studies of patients with loss of function mutations of APOC3, mutation carriers had lower levels of TR, higher HDL-C, lower, LDL-C, and lower risk for coronary heart disease compared to non-carriers [84,85].”
BackgroundYamamoto, T., Obika, S., Nakatani, M., Yasuhara, H., Wada, F., Shibata, E., Shibata, M., & Harada‐Shiba, M. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.004 · Cited by 11
“Both apoC-III-null subjects and apoC-III-deficient mice generally possess reduced plasma total cholesterol levels, as well as total triglycerides, when compared to those of normal controls (Gerritsen et al., 2005; Jong et al., 2001; Pollin et al., 2008; Takahashi et al., 2003).”
BackgroundResultInfluentialAragonès, G., Alonso‐Villaverde, C., Pardo-Reche, P., Rull, A., Beltrán‐Debón, R., Rodríguez‐Gallego, E., Fernández-Sénder, L., Camps, J., & Joven, J. (2011) · BMC Medical Genetics · doi:10.1186/1471-2350-12-120 · Cited by 12
“[5] in the polymorphism rs10892151, which is located 800 kb from the APOC3 gene cluster, prompted us to test the presence of a genetic association with lipid outcomes in our patients.”
BackgroundResultNovel polymorphisms associated with hyperalphalipoproteinemia and apparent cardioprotection
Oates, C. P., Koenig, D., Rhyne, J., Bogush, N., O’Connell, J. R., Mitchell, B. D., & Miller, M. J. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.10.021 · Cited by 11
Self-citationLightbourne, M., Wolska, A. T., Abel, B. S., Rother, K. I., Walter, M. F., Kushchayeva, Y. S., Auh, S., Shamburek, R. D., Remaley, A. T., Muniyappa, R., et al. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa191 · Cited by 11
“The clinical relevance of apoC-III is demonstrated by the observation that inactivating mutations in APOC3 are associated with lower triglyceride levels and reduced risk of ischemic cardiovascular disease [35-38], while polymorphisms leading to higher apoC-III are associated with higher triglycerides and increased pre…”
BackgroundBayesian model comparison for rare-variant association studies
Venkataraman, G. R., DeBoever, C., Tanigawa, Y., Aguirre, M., Ioannidis, A. G., Mostafavi, H., Spencer, C. C. A., Poterba, T., Bustamante, C. D., Daly, M. J., et al. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.11.005 · Cited by 11
Prospect and progress of gene therapy in treating atherosclerosis
Kivelä, A. M., Huusko, J., & Ylä‐Herttuala, S. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1084282 · Cited by 12
“Silencing of miR-302a by antagomirs was shown to increase plasma HDL levels and reduce atherogenesis in LDLR-deficient (LDLR-/-) mice [40].”
BackgroundInfluentialKhor, C. C., & Goh, D. L. M. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328336eae9 · Cited by 13
APOC3 Mutation, Serum Triglyceride Concentrations, and Coronary Heart Disease
Tsai, M. Y., & Ordovás, J. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.124669 · Cited by 11
Diabetes in Population Isolates: Lessons from Greenland
Grarup, N., Moltke, I., Albrechtsen, A., & Hansen, T. F. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.320 · Cited by 13
“Arg19Ter) in APOC3 has been shown to associate with decreased circulating triglyceride levels and lower risk of cardiovascular disease in Europeans [23, 24] and in a Greek isolate [25], and with decreased circulating triglyceride levels in an Amish population isolate living in the mid-west USA [26].”
BackgroundAssociation of Exome Sequences With Cardiovascular Traits Among Blacks in the Jackson Heart Study
Peloso, G. M., Lange, L. A., Varga, T. V., Nickerson, D. A., Smith, J. D., Griswold, M. E., Musani, S. K., Polfus, L. M., Mei, H., Gabriel, S., et al. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.116.001410 · Cited by 11
Wu, J., Wang, Y., Wang, A., Xie, J., & Zhao, X. (2018) · Scientific Reports · doi:10.1038/s41598-018-24157-w · Cited by 11
Kraaijenhof, J. M., Peletier, M. C., Nurmohamed, N. S., Hovingh, G. K., Alexander, V. J., Tsimikas, S., Stroes, E. S. G., & Kroon, J. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf478 · Cited by 10
New and Future Parenteral Therapies for the Management of Lipid Disorders
García, R. R., & Burkle, J. (2018) · Archives of Medical Research · doi:10.1016/j.arcmed.2019.01.001 · Cited by 12
Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy
Aslesh, T., & Yokota, T. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0771-8_5 · Cited by 11
Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer
Rouleau, M., Long, F. N. V., Turcotte, V., Caron, P., Lacombe, L., Aprikian, A. G., Fred Saad, C., Carmel, M., Chevalier, S., Lévesque, É., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02040-w · Cited by 10
“For example, loss-of-function variants of the APOC3 and PCSK9 genes reduce levels of triglycerides and low-density lipoprotein, respectively, and afford protection against coronary heart disease [2, 3].”
BackgroundReijnders, E., van der Laarse, A., Ruhaak, L. R., & Cobbaert, C. M. (2024) · Clinical Proteomics · doi:10.1186/s12014-024-09465-w · Cited by 12
Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics
Larach, D. B., Cuchel, M., & Rader, D. J. (2013) · Clinical Lipidology · doi:10.2217/clp.13.73 · Cited by 10
New Therapies for Coronary Artery Disease: Genetics Provides a Blueprint
Rader, D. J. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008535 · Cited by 10
Mitchell, B. D., Kalra, G., Ryan, K. A., Zhang, M., Sztalryd, C., Steinle, N., Taylor, S. I., Snitker, S., Lewis, J. P., Miller, M. J., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.11.006 · Cited by 11
“We have previously identified a null mutation (R19X; rs76353203) in APOC3 that is associated with a blunted response to TG AUC (15).”
BackgroundSelf-citationBiotechnology Approaches for the Treatment of Dyslipidemia
Parolini, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07017-6 · Cited by 10
“Conversely, carriers of loss-of-function mutations in APOC3 gene display a lipid-lipoprotein phenotype characterized by reduced TG, increased HDL-C and similar LDL-C levels, and a lower risk of CV disease compared with normal subjects [137, 138].”
BackgroundClemente‐Postigo, M., Queipo‐Ortuño, M. I., Valdivielso, P., Tinahones, F. J., & Cardona, F. (2010) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2010.08.014 · Cited by 10
“[12] recently studied a null mutation in the APOC3 gene which leads to lower fasting and nonfasting triglyceride levels, as well as lower LDL-C levels and higher HDL-C levels, and subclinical atherosclerosis was less frequent in carriers than in non-carriers of this null mutation.”
BackgroundMcPherson, R. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.311392 · Cited by 12
Semenkovich, C. F., Goldberg, A. C., & Goldberg, I. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00037-x · Cited by 23
Apolipoprotein C-III: The Small Protein With Sizeable Vascular Risk
Miller, M. J. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309493 · Cited by 10
Self-citationAncestral haplotype reconstruction in endogamous populations using identity-by-descent
Finke, K., Κourakos, M., Brown, G., Dang, H. T., Tan, S. J. S., Simons, Y. B., Ramdas, S., Schäffer, A. A., Kember, R. L., Bućan, M., et al. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008638 · Cited by 10
“More specifically, loss of function (LoF) mutations in some genes have shown to protect against disease [66, 67].”
BackgroundHigh Density Lipoproteins: Is There a Comeback as a Therapeutic Target?
von Eckardstein, A. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_536 · Cited by 13
Genome-wide significant risk loci for mood disorders in the Old Order Amish founder population
Humphries, E., Ahn, K., Kember, R. L., Lopes, F. L., Mocci, E., Peralta, J. M., Blangero, J., Glahn, D. C., Goes, F. S., Zandi, P. P., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02014-1 · Cited by 10
“Power analyses(68) suggest that this cohort is well-powered to detect population-enriched risk alleles with moderate to large effects, equivalent to those discovered in the OOA for non-psychiatric traits(14,23,69).”
Self-citationApolipoprotein C-III amyloidosis in white lions ( Panthera leo )
Kobayashi, N., Iwaide, S., Fukui, H., Une, Y., Itoh, Y., Hisada, M., & Murakami, T. (2024) · Veterinary Pathology · doi:10.1177/03009858241230100 · Cited by 10
“11,24,35 Notably, these ApoC-III mutations in humans are located close to the Val30 in lions.”
Insights from population-based analyses of plasma lipids across the allele frequency spectrum
Peloso, G. M., & Natarajan, P. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.01.003 · Cited by 10
JCL roundtable: Apolipoproteins as causative elements in vascular disease
Brown, W. V., Sacks, F. M., & Sniderman, A. D. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.10.003 · Cited by 9
Shah, S. H., Guyatt, A. L., Ladroue, C., Kumari, M., Drenos, F., Shah, T., Talmud, P. J., Casas, J. P., Lowe, G. D. O., Rumley, A., et al. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-02-0087 · Cited by 9
Therapeutic inhibition of apoC-III for the treatment of hypertriglyceridemia
Bell, T. A., Graham, M. J., Baker, B. F., & Crooke, R. M. (2015) · Clinical Lipidology · doi:10.2217/clp.15.7 · Cited by 10
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
Bell, D. A., & Watts, G. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.001 · Cited by 10
Treatment of Hyperlipidemia Changes With Level of Kidney Function—Rationale
Ananthakrishnan, S., & Kaysen, G. A. (2016) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2015.12.004 · Cited by 10
Hamadneh, L., Al-Essa, L. Y., Hikmat, S., Al‐Qirim, T. M., Sheikha, G. M. A., Al-Hiari, Y. M., Azmy, N., & Shattat, G. F. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-2983-3 · Cited by 9
“Studies on human gene expression of apoc3 show that mutations in the gene lead to lower blood triglycerides levels and result in coronary protective effects [18].”
BackgroundSomers, M., Loohuis, L. M. O., Aukes, M. F., Paşaniuc, B., de Visser, K. L., Kahn, R. S., Sommer, I. E., & Ophoff, R. A. (2017) · Genes · doi:10.3390/genes8050133 · Cited by 9
Genetics of Coronary Atherosclerosis
Aragam, K. G., & Kathiresan, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00003-0 · Cited by 9
Genetics of remnant cholesterol
Wulff, A. B., & Nordestgaard, B. G. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000991 · Cited by 8
Antisense oligonucleotides in the treatment of lipid disorders: pitfalls and promises.
Besseling, J., Hovingh, G. K., & Stroes, E. S. G. (2013) · PubMed · Cited by 9
Genetics for the Identification of Lipid Targets Beyond PCSK9
Wang, L. R., & Hegele, R. A. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.11.003 · Cited by 9
“A study in a Pennsylvania Amish population found that carriers of a rare APOC3 gene knock-out variant had favorable lipids and decreased atherosclerosis (51).”
Research Into the Genetic Component of Heart Disease: From Linkage Studies to Genome-Wide Genotyping
Elosúa, R., Lluís-Ganella, C., & Lucas, G. (2009) · Revista Española de Cardiología · Cited by 9
Malalla, Z. H. A., Al‐Serri, A., Alaskar, H., Al-Kandari, W. Y., & Al‐Bustan, S. A. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1165-6 · Cited by 8
Björnson, E., Adiels, M., Taskinen, M., Packard, C. J., & Borén, J. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01399-y · Cited by 9
“LOF carriers were found to have markedly reduced coronary artery calcification scores [ 40].”
Bazarbashi, N., & Miller, M. J. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.11.006 · Cited by 10
Self-citationDetera‐Wadleigh, S. D., Kassem, L., Besancon, E., Lopes, F. L., Akula, N., Sung, H., Blattner, M., Sheridan, L., Lacbawan, L. N., Garcia, J., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02641-w · Cited by 9
Miller, M. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001136 · Cited by 7
Self-citationPackard, C. J., Taskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Andersson, L. K., Adiels, M., & Borén, J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119166 · Cited by 7
Multiple dimensions of stress vs. genetic effects on depression
Kvarta, M. D., Bruce, H. A., Chiappelli, J., Hare, S., Goldwaser, E. L., Sewell, J., Sampath, H., Lightner, S., Marshall, W., Hatch, K. S., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01369-9 · Cited by 8
Self-citationUsing human genetics to discover new therapeutic targets for plasma lipids
Cohen, J. C. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12521 · Cited by 7
Clarifying complex inheritance: apolipoprotein C3 and atherosclerosis
Galton, D. J. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000425 · Cited by 7
Is APOC3 the driver of cardiovascular disease in people with type I diabetes mellitus?
Ginsberg, H. N., & Reyes‐Soffer, G. (2019) · Journal of Clinical Investigation · doi:10.1172/jci131333 · Cited by 7
Metadata
- Authors
- Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., Mitchell, B. D., Miller, M., O'Connell, J. R., & Shuldiner, A. R.
- Affiliations
- University of Maryland, Baltimore (US)
- Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
- Corresponding author
- Pollin, Toni I.
- ORCID
- Venue
- Science
- Published
- 2008-12-12
- Volume
- 322
- Issue
- 5908
- Pages
- 1702-1705
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2673993
- OpenAlex
- W2061100095
- Semantic Scholar
- d46146fa9f89ec4722b99bade97f6a1d685409c0
- Cited by
- 688
- References
- 34
- Citations by year
- 2026: 31 · 2025: 33 · 2024: 30 · 2023: 30 · 2022: 30 · 2021: 41 · 2020: 38 · 2019: 36 · 2018: 52 · 2017: 51 · 2016: 54 · 2015: 49 · 2014: 55 · 2013: 43 · 2012: 23
- FWCI
- 22.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01-AG-18728, R01AG018728)
- National Heart, Lung, and Blood Institute (U01HL72515, U01HL084756, U01HL072515, R01HL088119)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK072488)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR046838)
- National Center for Research Resources (M01RR016500, M01RR000052, M01RR 16500)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, plasma lipid profile, triglycerides, HDL cholesterol, LDL cholesterol, coronary artery calcification, subclinical atherosclerosis, cardioprotection, coronary artery disease, lipolysis
- MeSH terms
- Adult, Cholesterol, Christianity, Coronary Artery Disease, Dietary Fats, Fasting, Female, Haplotypes, Heterozygote, Humans, Lipids, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Mutation, Pedigree, Pennsylvania, Risk Factors, Triglycerides, Linkage Disequilibrium, Polymorphism, Single Nucleotide, Apolipoprotein C-III, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.